Satish K. Chitneni, Ph.D.

  • Associate Professor of Radiology
  • Director, Translational PET/CT Molecular Imaging Center
Department/Division
  • Research
Address DUMC Box 3949
Durham, NC 27710
Telephone 919-684-7809
Fax 919-684-7122
Training
  • PhD, Katholieke Universiteit Leuven (Belgium), 2007
  • Chitneni SK, Reitman ZJ, Gooden DM, Yan H, Zalutsky MR. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. doi: 10.1016/j.ejmech.2016.04.066. 2016 Apr 28;119:218-230 Abstract
  • Pruszynski M, Koumarianou E, Vaidyanathan G, Chitneni S, Zalutsky MR. D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. doi: 10.1016/j.nucmedbio.2014.08.007. 2015 Jan;42(1):19-27 Abstract
  • Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. doi: 10.2967/jnumed.114.137448. 2014 Jul;55(7):1192-7 Abstract
  • Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP. Copper signaling axis as a target for prostate cancer therapeutics. doi: 10.1158/0008-5472.CAN-13-3527. 2014 Oct 15;74(20):5819-31 Abstract
  • Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. doi: 10.2967/jnumed.112.116293. 2013 Aug;54(8):1339-46 Abstract
  • Chitneni SK, Bida GT, Dewhirst MW, Zalutsky MR. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). doi: 10.1016/j.nucmedbio.2012.05.006. 2012 Oct;39(7):1012-8 Abstract
  • Deroose CM, Chitneni SK, Gijsbers R, Vermaelen P, Ibrahimi A, Balzarini J, Baekelandt V, Verbruggen A, Nuyts J, Debyser Z, Bormans GM, Mortelmans L. Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. doi: 10.1016/j.nucmedbio.2012.06.014. 2012 Nov;39(8):1266-74 Abstract
  • Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. doi: 10.2967/jnumed.110.075663. 2011 Feb;52(2):165-8 Abstract
  • Celen S, Koole M, De Angelis M, Sannen I, Chitneni SK, Alcazar J, Dedeurwaerdere S, Moechars D, Schmidt M, Verbruggen A, Langlois X, Van Laere K, Andrés JI, Bormans G. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. doi: 10.2967/jnumed.110.077040. 2010 Oct;51(10):1584-91 Abstract
  • Chitneni SK, Serdons K, Evens N, Fonge H, Celen S, Deroose CM, Debyser Z, Mortelmans L, Verbruggen AM, Bormans GM. Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. 2008 May 2;1189(1-2):323-31 Abstract
  • Chitneni SK, Garreau L, Cleynhens B, Evens N, Bex M, Vermaelen P, Chalon S, Busson R, Guilloteau D, Van Laere K, Verbruggen A, Bormans G. Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT. 2008 Jan;35(1):75-82 Abstract
  • Fonge H, Chitneni SK, Lixin J, Vunckx K, Prinsen K, Nuyts J, Mortelmans L, Bormans G, Ni Y, Verbruggen A. Necrosis avidity of (99m)Tc(CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis. 2007 Nov-Dec;18(6):1924-34 Abstract
  • Chitneni SK, Deroose CM, Balzarini J, Gijsbers R, Celen SJ, de Groot TJ, Debyser Z, Mortelmans L, Verbruggen AM, Bormans GM. Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography. 2007 Mar 8;50(5):1041-9 Abstract